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Abstract We recently demonstrated that 2,3,4,5,6-pentahy-
droxyxanthone (X5) inhibits the in vitro growth of both 
chloroquine-sensitive and multidrug-resistant strains of P. 
falcipamm. To study the molecular basis of its antimalarial 
action, we tested X5 and selected hydroxyxanthone analogs as 
inhibitors of in vitro heme polymerization in a low ionic strength 
phosphate solution at mildly acidic pH. We found that addition 
of 1 Eq. of X5 resulted in complete inhibition of polymerization 
in this system whereas addition of up to 40 Eqs. of standard 
antimalarial compounds (chloroquine, primaquine, quinacrine, 
artemisinin and méthylène blue) had no such effect although 
these compounds did co-precipitate with heme. The antimalarial 
potency of the hydroxyxanthones correlated well with their 
ability to inhibit in vitro heme polymerization in our assay, 
suggesting that these compounds exert their antimalarial action 
by preventing hemozoin formation. Based on the observed 
structure-activity relationships, we propose a model displaying 
possible interactions between hydroxyxanthones and heme. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Malaria is a disease of enormous importance by any stand-
ard of measure. Billions of people live in the regions where, 
according to recent figures from the World Health Organiza-
tion, malaria causes 100 million clinical episodes and over 
1 million deaths per year [1]. The recent emergence and rapid 
spread of chloroquine-resistant strains of Plasmodium falcipa-
mm threaten to increase the annual death toll. As a result, 
there is a great need for development of mechanistically novel 
antimalarial drugs. 
The malarial parasite infects red blood cells, ingesting and 
degrading hemoglobin in the acidic food vacuole [2]. Proteo-
lysis of hemoglobin yields amino acids for protein synthesis as 
well as toxic heme [3]. As the parasite cannot enzymatically 
cleave the porphyrin ring, heme is 'detoxified' by conversion 
to an insoluble polymer, hemozoin [2]. It has been suggested 
that hemozoin formation is inhibited by the 4-aminoquino-
lines, such as chloroquine, quinine and amodiaquin [4,5], 
although the evidence appears to be controversial [6]. 
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We have recently identified 2,3,4,5,6-pentahydroxyxanthone 
(X5) as a potent antimalarial drug with equal activity against 
multidrug-resistant strains of P. falciparum [7]. We were, 
therefore, interested in exploring the mode of action of this 
novel compound in an effort to identify structural features 
critical for its antimalarial action. Here, we describe the com-
plexation of X5 with soluble heme, introduce a slight but 
significant modification of the in vitro heme polymerization 
assay and demonstrate the ability of X5 and related xanthones 
to inhibit this process. 
2. Materials and methods 
2.1. Chemicals and reagents 
Hemin chloride, artemisinin, quinacrine dihydrochloride hydrate 
and primaquine diphosphate were purchased from Aldrich Chemical 
(Milwaukee, WI, USA). [3H]Ethanolamine was obtained from Amer-
ican Radiolabeled Chemicals (St. Louis, MO, USA). Chloroquine 
diphosphate was obtained from Sigma Chemical (St. Louis, MO, 
USA) and quinine sulfate was from Matheson Coleman and Bell 
(Cincinnati, OH, USA). Xanthone (9-xanthenone) was purchased 
from Fluka (Buchs, Switzerland). Detailed methods for synthesis of 
the hydroxylated xanthones will be published elsewhere. 
2.2. Culture of P. falciparum 
The chloroquine-susceptible D6 clone of P. falciparum has been 
previously described [8]. The parasites were cultured in Group A+ 
human erythrocytes, suspended at a 2% hematocrit in RPMI-1640 
(pH 7.15) which contained 3 g/1 glucose, 50 ug/1 gentamicin, 10% 
human serum and maintained at 37°C in a gas mixture of 5% 0 2 , 
5% C0 2 and 90% N2 [9]. 
2.3. Drug testing 
In vitro antimalarial activity of the test compounds was assessed by 
following incorporation of [3H]ethanolamine (50 Ci/mmol) into para-
site lipids as described by Elabbadi et al. [10] with minor modifica-
tions. The experiments were set up in duplicate in 96-well plates with 
varying concentrations of the xanthone (10~9 to 10~4 M) across the 
plate in a total volume of 200 ul and at a final red blood cell concen-
tration of 2% (v/v). An initial parasitemia of 0.2% was attained by 
addition of normal uninfected red cells to a stock culture of infected 
cells. Although no special attempts were made to use synchronous 
cultures, most experiments were begun with cultures in which 
~50% of infected erythrocytes harbored parasites at the mature 
trophozoite stage of development. Radiolabeled ethanolamine (1 
uCi in 20 |i.l of medium) was then added after 48 h of incubation 
and the experiment was terminated after 72 h by collecting the cells 
onto glass fiber filters with an automated Skatron multiwell harvester. 
Stock solutions of the xanthones were made by dissolving the com-
pounds into dimethylsulfoxide at 10 mM. The concentration of drug 
giving 50% inhibition of label incorporation (IC50) was calculated 
from a computer-generated semi-logarithmic dose-response curve. 
2.4. Complex formation between heme and X5 
The complexation of heme with X5 was tested spectrophotometri-
cally as described by Vossen et al. [11] using a Cary 4 Bio UV/visible 
scanning spectrophotometer (Varian). A stock solution of 10 mM 
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hemin chloride in 0.1 M NaOH was prepared freshly and incubated at 
37°C for at least 30 min to ensure complete dissolution of the mono-
mer. A stock solution of 10 mM X5 in dimethylformamide was pre-
pared freshly. The stock solutions were diluted to 25 uM with ice-cold 
0.02 M phosphate (pH 5.2). Dimethylformamide (0.25% v/v) was 
added to the hemin control. Sample and reference tandem cuvettes 
were filled each with hemin and X5 solutions (0.8 ml) and the base 
line was recorded (235-500 nm). The temperature of the cell compart-
ment was kept at 5°C to retard the heme polymerization process. 
Then, the solutions in the sample cuvette were mixed and the UV7 
visible difference spectra were recorded over 45 min of incubation. 
2.5. Syntheses of heme polymers 
Hemin stock solution was added to 3 glass beakers containing 1 1 of 
0.02 M sodium phosphate, 0.02 M sodium acetate and 4 M sodium 
acetate solutions, respectively, to yield a final concentration of 25 uM. 
The pH of all solutions was 5.2. After 2 h of incubation at 37°C 
followed by overnight incubation at room temperature, the precipi-
tates were washed 10 X with deionized water, dried in vacuo and 
characterized by means of differential solubility, elemental analysis 
and IR spectroscopy. 
2.6. In vitro heme polymerization assay 
Heme polymerization was carried out in 0.02 M phosphate (pH 5.2) 
at 37°C in the absence of proteins. A 10 mM stock solution of hemin 
chloride in 0.1 M NaOH was prepared freshly and incubated at 37°C 
for at least 1 h. Xanthones were dissolved in dimethylformamide at 10 
mM and diluted into 10 ml of pre-warmed phosphate solution to a 
final concentration of 25 |iM. Polymerization was initiated by addi-
tion of 25 ul of the hemin stock solution to the test sample to yield a 
final concentration of 25 |xM heme. 25 ill of dimethylformamide was 
added to the control sample. After 7, 30, 60, 120 and 210 min of 
incubation at 37°C, a 1-ml aliquot was withdrawn, transferred into 
an Eppendorf tube and centrifuged at 14000Xg for 2 min at room 
temperature to pellet the polymer. The soluble fraction was then 
transferred to a semi-microcuvette (polymethylacrylate, VWR) and 
its absorption was measured at 360 nm against a blank of the test 
compound in buffer. Control experiments indicated that: (1) the pH 
of the phosphate solution did not change upon addition of the re-
agents or during the polymerization process; and (2) the amount of 
dimethylformamide used in this assay did not significantly affect the 
rate of polymerization. To estimate the effect of test compounds on 
heme polymerization at a given time of incubation, the percentage of 
soluble hemin remaining in the sample was calculated using the fol-
lowing formula: 
% soluble hemin : ■ (
d m g + h e m i n > t ^-(drag)t ; . ] n Q 0 / 
A(hemin)t=0 
where A(drug+hemin)t is the absorption (360 nm) of the soluble fraction 
in the drug-hemin sample after various times of incubation; A(drug)t is 
the absorption of the drug alone; and A(hemin)t=0 is the absorption of 
the hemin control sample (25 (iM) measured immediately upon addi-
tion of the hemin stock solution. 
The dose-dependent inhibition of heme polymerization was eval-
uated as described above, except the concentration of each drug 
was varied in the range of 0-1 mM. The reactions were allowed to 
proceed for 2 h in a 37°C waterbath. After incubation, the polymer 
was pelleted as described above and the absorption (360 nm) of each 
soluble fraction was measured against a blank containing the drug 
alone in buffer. The IC50 values were determined by non-linear regres-
sion analysis of the dose-response curves of percentage inhibition of 
heme polymerization vs. drug concentration. 
3. Results 
3.1. Complex formation between heme and X5 
Based on structural features of X5, we predicted that it 
would form a complex with free heme. We used UV/visible 
250 300 350 400 
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Fig. 1. UV/visible difference spectra induced by binding of X5 to heme in 0.02 M phosphate (pH 5.2) at 5°C for the time points indicated. 
Scan speed, 75 nm/min. 
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Fig. 2. IR spectra of hematin-acetate (0.02 M) incubation product (top), hematin-phosphate (0.02 M) incubation product (middle) and hema-
tin-acetate (4 M) incubation product (bottom). 
difference spectroscopy to measure the optical signal produced 
upon interaction between heme and X5. Dual tandem cuvettes 
allowed direct comparison of the same amounts of heme and 
X5 mixed in the sample cuvette and separated in the reference 
cuvette. By this experimental design the contributions from 
slight differences in the heme, X5 and dirnethylformamide 
concentrations to the difference spectra were cancelled, i.e. 
only the effects of complexation are observed. The method 
allows the continuous and sensitive monitoring of spectral 
changes without subsampling from the three different solu-
tions. Fig. 1 shows the family of UV/visible difference spectra 
induced by binding of X5 to heme over 45 min of incubation. 
The spectra contain a difference peak at 270 nm which de-
creased with time, a dip at 327 nm and shoulders at —250 
and «420 nm which increased with time. These changes are 
indicative of the red shifts in the UV (240-260 nm) and visible 
Table 1 
Physical and chemical properties of heme and heme polymers 
(320^100 nm) absorbance produced upon formation of the 
heme-X5 complex. Interestingly, in preliminary experiments 
in which the samples were kept at 37°C, we detected by visual 
inspection the formation of a flocculent brown precipitate in 
the heme control sample within 1 h of incubation, while no 
such phenomenon was observed in the test sample containing 
both heme and X5. Substitution of 0.02 M phosphate with 
0.02 M acetate at the same pH yielded identical results 
although at a high acetate concentration (4 M) X5 failed to 
prevent precipitation. 
3.2. Characterization of heme polymers 
The precipitates formed as described above (i.e. in 0.02 M 
phosphate, 0.02 M acetate and 4 M acetate; pH 5.2, 37°C) 
were characterized by means of differential solubility, elemen-
tal analysis and IR spectroscopy. As shown in Table 1, the 
Sample 
Hematin 
Malarial hemozoinab 
Hematin-phosphate 
(0.02 M) incubation product 
Hematin-acetate 
(0.02 M) incubation product 
Hematin-acetate 
(4 M) incubation product 
Solubility Elememtal composition 
CH3OH C2H5OH CH3COOH/ SDS Dimethyl 
H2O/CH3OH (2.5%) sulfoxide 
(1.5:0.5:8) 
+ 
+ 
%C %H %N %Fe 
5.3 
5.2±0.2C 
%P 
0 
!.7±0.2C 8.7±0.2C NDd 
Î.410.3 8.8±0.5 <0.1 
64.5 
64.6 ±0.! 
64.3 ±0.3 5.4 ±0.3 
64.4 ±0.3 5.3 ±0.3 8.4 ±0.3 8.4 ±0.5 <0.1 
59.3 ±0.3 5.2 ±0.3 7.2 ±0.3 7.0 ±0.5 <0.1 
"Pandey et al. [12]. bSlater et al. [13]. cFitch et al. [14]. dND, not determined. 
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Fig. 3. pH profile for in vitro heme polymerization in 0.02 M phos-
phate (37°C, 2 h of incubation). Values are the mean of duplicate 
determinations. 
solubility properties of the phosphate (but not 4 M acetate)-
derived material were identical to those reported for hemozoin 
('malarial pigment') [12,13]. The precipitate formed in 0.02 M 
acetate solution was partially soluble in alcohols and the 
methanol/acetic acid/water mixture. Elemental analyses 
showed that the percentages of carbon, hydrogen, nitrogen 
and iron in the 0.02 M phosphate and 0.02 M acetate-derived 
products corresponded closely to the values reported for he-
mozoin [14]. The 4 M acetate-derived product had an elemen-
tal composition consistent with that of a hematin-triacetate 
adduct. All of the products exhibited increased IR absorbance 
in the 1600-1650 cm - 1 region (Fig. 2), indicative of the car-
boxylate coordination to iron [13]. In all, these data suggest 
that the precipitate formed upon incubation of hemin in 0.02 
M phosphate solution is a heme polymer chemically analo-
gous to hemozoin and distinct from the product formed upon 
incubation of hemin in 0.1^l.5M acetate buffers [5,12,15]. 
3.3. Heme polymerization and its inhibition by X5 
Since the preliminary results indicated that X5 inhibited 
heme polymerization, we developed an assay based on the 
spectrophotometric detection of soluble heme. Under the con-
ditions of our assay, heme polymerization was pH-dependent 
(pH 4.5-5.5) (Fig. 3), occurred spontaneously and was > 95% 
complete within 2 h of incubation (Fig. 4). As described in 
Section 2, the reaction mixture was prepared by dilution of a 
hemin stock solution into a mildly acidic phosphate solution 
(pH 5.2). 
Addition of 1 Eq. of X5 resulted in complete inhibition of 
polymerization in a phosphate solution (Fig. 4, panel A). Ad-
dition of X5 to polymerized heme did not reverse the process. 
This, as well as the ability of X5 to alter the spectral proper-
ties of heme, strongly suggests that X5 inhibits heme polymer-
ization through the formation of a soluble complex with free 
heme. 
3.4. Inhibition of heme polymerization by other xanthones 
Structure-activity relationships were determined for xan-
thones as inhibitors of spontaneous heme polymerization (Ta-
ble 2 ). The IC50 values are the average of at least two in-
dependent determinations of full dose-response curves. 
Xanthone and the tested monohydroxyxanthones did not ex-
hibit any inhibitory activity in our assay. Moderate inhibitory 
activity (i.e. IC50 of »8 -20 uM) was observed for the com-
pounds bearing a single hydroxy group at either 4- or 5-posi-
tion whereas the greatest activity was observed for xanthones 
containing hydroxy groups at both positions. For example, 
2,3,4-trihydroxyxanthone exhibited an IC50 of 16.5 |xM, while 
2,3,4,5,6-pentahydroxyxanthone (X5) yielded a value of 1.2 
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Fig. 4. Panel A: spontaneous heme polymerization in 0.02 M phosphate (pH 5.2) at 37°C in the absence (open diamonds) and presence (black 
diamonds) of X5. Values are the mean± S.D. of three independent experiments. Panel B: dose-response effect of X5 on spontaneous heme pol-
ymerization in 0.02 M phosphate (pH 5.2) at 37°C. Initial heme concentration is 25 |xM. 
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Table 2 
Inhibition of in vitro heme polymerization by xanthones 
Compound name 
2-hydroxyxanthone 
3 -hydroxyxanthone 
1,3-dihydroxyxanthone 
3,6-dihydroxyxanthone 
4,5 -dihydroxyxanthone 
2,3,4-trihydroxyxanthone 
3,4,5,6-tetrahydroxyxanthone 
2,3,4,5,6-pentahydroxyxanthone 
(X5) 
1,3,5,6,7-pentahydroxyxanthone 
2,3,4,5,6,7-hexahydroxyxanthone 
(X6) 
2,3,4,5,6-pentamethoxyxanthone 
2,3,4,5,6-pentaacetylxanthone 
Compound structure 
O 
O 
OH O 
o 
H O ' ^ ^ O ^ ^ O H 
0 
OH OH 
O 
H O ^ Y ^ O ^ ^ 
OH 
O 
H O ^ Y ' o ^ y L l H 
OH OH 
HO^Y^O^Y^OH 
OH OH 
OH O 
H O ^ ^ ^ O ^ Y O H 
OH 
0 
H O ^ ^ J L ^ J D H 
HO^Y^O^Y^OH 
OH OH 
0 
M e O ^ ^ J L ^ 
M e O ^ N ^ O ^ Y * ^ O M e 
OMe OMe 
A c O ^ Y ^ O y ^ OAc 
OAc OAc 
IC50 nM, 
P. falciparum 
clone D6 
50 
>100 
75 
>100 
16 
40 
5 
0.4 
1 
0.1 
>100 
0.075 
IC50, |iM 
in vitro heme 
polymerization 
>1000 
>1000 
>1000 
>500 
14 
17 
2.5 
1.2 
9 
1.4 
>1000 
>1000 
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by Sullivan et al. [14,16]. We monitored the concentration of 
chloroquine by measuring its absorption at 340 nm in the 
presence of an equimolar concentration of polymerizing 
heme (25 uM). Indeed, we found that the concentration of 
soluble chloroquine decreased ~ 35% after 2 h of incubation, 
indicative of the chloroquine/heme polymer co-precipitation 
phenomenon. 
Similar spectroscopic studies were then performed with oth-
er antimalarial agents. Primaquine, quinacrine and méthylène 
blue, which are positively charged under mildly acidic condi-
tions, co-precipitated with the heme polymer (producing a 
distinctive change in the color of the polymer in the last 
case), possibly due to association with free carboxyl groups 
of the heme polymer and 7t-7t interactions between the aro-
matic systems. 
4. Discussion 
Fig. 5. A model for one possible docking orientation of a symmetri-
cal polyhydroxyxanthone (X6) to heme. Asterisks indicate the heme 
carboxyl groups. 
uM (Fig. 4, panel B). Consistent with this structure-activity 
profile, the 4,5-hydroxylated xanthones also exhibited the 
most pronounced in vitro antimalarial activity (Table 2). Fur-
thermore, pentamethoxy-X5 and pentaacetyl-X5 were inac-
tive in this assay though the latter was shown to be a potent 
antimalarial agent. Presumably, pentaacetyl-X5 is hydrolys-
able in infected red blood cells by a non-specific esterase 
whereas pentamethoxy-X5 is not. 
3.5. Inhibition of heme polymerization by known antimalarial 
agents 
We evaluated known antimalarials (e.g. chloroquine, prima-
quine, quinacrine, artemisinin and méthylène blue) as inhib-
itors of heme polymerization under our in vitro assay condi-
tions. As shown in Table 3, we found that the addition of 1-
40 Eqs. of these compounds had no effect on the rate of in 
vitro polymerization as determined spectrophotometrically. 
We, therefore, decided to investigate the possibility that chlo-
roquine might co-precipitate with the heme polymer as shown 
previously by Fitch and Kanjananggulpan and, more recently, 
The digestive vacuole is an acidic proteolytic compartment 
central to the metabolism of the Plasmodium parasite and may 
be considered as its Achilles' heel [3,6]. In this vacuole, hemo-
globin is degraded to provide amino acids for parasite growth. 
Hemoglobinolysis also yields toxic heme, which serves as a 
reservoir of iron for parasite ferroproteins, although most of 
the heme is detoxified via polymerization into insoluble hemo-
zoin. The mechanism of heme polymerization remains un-
known. Slater and Cerami [17] initially proposed that the 
formation of hemozoin is an enzyme-mediated process. How-
ever, Egan et al. [5] and Dorn et al. [15] have suggested that 
heme polymerization is a spontaneous process when carried 
out in acidic acetate solutions (0.1^4.5 M, pH 4.2-5.0). It 
would appear that acetate will compete with the propionate 
side-chains of the porphyrin for the iron-centered coordina-
tion sites, resulting in formation of heme-acetate adducts [12] 
and polymer chain termination; hence, the increased solubility 
of the acetate-derived products ([12] and this report) and the 
splitting of the IR band (~1650 cm - 1) . In this report, we 
describe the development and characterization of an in vitro 
heme polymerization assay which proceeds under conditions 
likely to be present in the acidic vacuole. The product of our 
modified assay appears to be chemically similar to hemozoin. 
The low-ionic strength (20 mM) phosphate solution was used 
since this concentration is in the physiological range for most 
prokaryotic and eukaryotic cells [18]. The only carboxylate 
moieties present in the reaction mixture were those contrib-
uted by heme itself. The optimal pH range for heme polymer-
ization was 4.5-5.5 at 37°C. Polymerization at higher pH did 
Table 3 
In vitro ability of antimalarial compounds to inhibit heme polymerization and to co-precipitate with the polymerizing heme 
Compound name Inhibition of in vitro heme polymerization Co-precipitation with heme polymer in vitro" 
Artemisinin 
Cloroquine 
Méthylène blue 
Primaquine 
Quinacrine 
NDb 
+c (24%) 
+d (37%) 
+e (21%) 
+f (50%) 
"Determined as decreased absorbance of the antimalarial compound in the presence of equimolar (25 uM) polimerizing heme after 2 h of 
incubation; values in parentheses are the mean of duplicate determinations. 
bND, not determined; no characteristic UV/visible absorbance peaks (250-750 nm). 
cMonitored at 328 and 342 nm. 
dMonitored at 290 and 665 nm; precipate becomes blue-green in color. 
eMonitored at 258 nm. 
fMonitored at 275 nm. 
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not occur. Physical and chemical properties of the reaction 
product suggest that it is, indeed, a heme polymer with the 
carboxylate side-chain of one heme linked to the central ferric 
ion of the next, the structure proposed for ß-hematin and 
hemozoin [6,13,19]. 
In a previous report, we put forth a 'xanthone hypothesis' 
to explain the potent antimalarial synergy between oxidant 
drugs and exifone [7]. We speculated that exifone functions 
as a prodrug yielding X5 upon free-radical hydroxylation. 
Based on in vitro characterization of this transformation, we 
proposed that the cyclodehydration event takes place in the 
digestive vacuole. We subsequently synthesized X5 and dem-
onstrated its remarkable in vitro antimalarial activity [20]. 
Herein, we present evidence relating to the mode of action 
of this xanthone. Our findings suggest that X5 forms soluble 
complexes with heme monomers or oligomers and interferes 
with hemozoin formation. Such action may prevent detoxifi-
cation of free heme, starve the parasite for iron or significantly 
increase the osmotic pressure within the parasite digestive va-
cuole. It is to be noted that the polymerization process must 
sequester all or most of the freed heme, which otherwise 
would accumulate to a concentration of up to 0.4 M [16]. 
The relative abilities of X5 and some of its analogs to inhibit 
in vitro heme polymerization are in good correlation with 
their in vitro antimalarial activities and are indicative of the 
following structure-activity relationships: (1) in general, a 
higher degree of hydroxylation is favored for the inhibitory 
activity; and (2) hydroxylation at 4- and 5-positions appears 
to be absolutely critical. Based on these observations, we have 
developed a model for one possible docking orientation of a 
symmetrical polyhydroxyxanthone (X6) to a heme monomer 
(Fig. 5) displaying several significant interactions: (1) between 
the heme iron and the carbonyl oxygen; (2) between the two 
planar aromatic systems; and (3) between the carboxylate 
side-groups of the heme and the 4- and 5-position hydroxyls 
of the xanthone. Moreover, this model predicts that chemical 
modifications at the 4- and/or 5-positions which improve as-
sociation with the heme carboxylate groups will result in even 
greater antimalarial activity. Xanthone congeners containing 
positively charged groups (e.g. alkylamines or amidines) at 
these positions are being prepared to test this model. 
Certain antimalarial drugs have been shown to bind free 
heme in mildly basic phosphate solutions [4,21,22] or to in-
hibit formation of heme polymers in acidic acetate solutions 
[5,15,23,24]. In this study, we have evaluated a number of 
these compounds as inhibitors of in vitro heme polymeriza-
tion and were unable to observe such effects under our assay 
conditions (i.e. in a mildly acidic phosphate solution). For 
example, addition of 10 mM chloroquine (i.e. 400 Eqs.) to 
the sample containing 25 (J,M free heme did not affect the 
rate of polymerization since no detectable levels of soluble 
heme were observed in the sample after 2 h of incubation. 
However, we detected co-precipitation of chloroquine and 
heme which is consistent with the findings of Fitch et al. 
[14] and Sullivan et al. [16] who have recently studied hemo-
zoin chain extension in the presence of heme substrate and 
aminoquinolines (chloroquine and quinidine) in acidic acetate 
solutions and found that these compounds are incorporated 
into the growing polymer (see Fig. 3 of [16]). None of the 
other antimalarials tested in our assay (artemisinin, prima-
quine, quinacrine or méthylène blue) inhibited spontaneous 
heme polymerization either although primaquine, quinacrine 
and méthylène blue were found to co-precipitate with the 
polymer. These observations are consistent with the notion 
that aminoquinolines and other existing antimalarials do not 
directly inhibit in vivo hemozoin formation to exert their anti-
malarial action [6,16,23]. 
Taken together, our data suggest that xanthones act in a 
unique fashion to kill Plasmodium parasites through forma-
tion of soluble complexes with heme, thereby inhibiting the 
process of heme polymerization. 
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